{"id":"bromfenac-ophthalmic-solution-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Corneal adverse events (rare)"}]},"_chembl":{"chemblId":"CHEMBL1077","moleculeType":"Small molecule","molecularWeight":"334.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a topical ophthalmic NSAID, bromfenac penetrates ocular tissues and suppresses COX-1 and COX-2 activity, thereby decreasing prostaglandin-mediated inflammatory mediators. This reduces ocular inflammation, pain, and swelling associated with surgical procedures and inflammatory conditions of the eye.","oneSentence":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:23.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following ocular surgery"},{"name":"Ocular itching associated with allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":"Pain, Intravitreal Injection, Pain, Acute","enrollment":97},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01478555","phase":"PHASE2","title":"A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-01","conditions":"Dry Eye Disease","enrollment":""},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT00758784","phase":"PHASE2","title":"Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-08-13","conditions":"Dry Eye Disease","enrollment":38},{"nctId":"NCT01212471","phase":"PHASE3","title":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":840},{"nctId":"NCT03521791","phase":"PHASE4","title":"Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-12-13","conditions":"Pterygium, Ocular Pain, Ocular Inflammation","enrollment":166},{"nctId":"NCT04022811","phase":"PHASE4","title":"Effect of Bromfenac on Pain Related to Pterygium Surgery","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-10","conditions":"Pterygium, Pain","enrollment":60},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":"Treatment of Ocular Inflammation Associated With Cataract Surgery","enrollment":57},{"nctId":"NCT02973880","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2017-10-15","conditions":"Cataract Extraction, Cataract","enrollment":180},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":"Cataract, Retinal Edema, Inflammation","enrollment":50},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT02681679","phase":"NA","title":"Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":"Cataract","enrollment":60},{"nctId":"NCT01367249","phase":"PHASE3","title":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Pain, Inflammation, Cataract","enrollment":440},{"nctId":"NCT00423007","phase":"PHASE3","title":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Allergic Conjunctivitis","enrollment":90},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Pain, Inflammation","enrollment":299},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":"Cataracts","enrollment":49},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":"Diabetic Macular Edema","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bromfenac Ophthalmic Solution A","genericName":"Bromfenac Ophthalmic Solution A","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following ocular surgery, Ocular itching associated with allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}